Our current methods of generating the CD40 - B
vaccine from lymphoma patients are laborintensive and require specialized laboratory equipment that is not available in most facilities.
Not exact matches
As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in
lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in
vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes
from HLA - matched donors who were vaccinated with a
lymphoma idiotype.
Important reports
from the Weiner lab include the first DNA
vaccine studied for HIV as well as for cancer immune therapy of cutaneous T cell
lymphoma, the early development of DNA encoded genetic adjuvants, including IL - 12, advances in gene optimization, and advances in electroporation technologies resulting in improved gene delivery.
Since the development of the first FeLV
vaccine, coupled with better management measures (and an increased understanding of virus transmission), global rates of FeLV - related
lymphoma have decreased
from 70 percent to 15 percent.